The efficacy of Callispheres drug-eluting beads in the treatment of squamous non-small cell lung cancer in the elderly

doi:10.3877/cma.j.issn.2095-8757.2020.03.003

Abstract

Abstract:

Objective

To investigate the efficacy and safety of CalliSpheres drug-loaded microsphere through bronchial artery chemoembolization (BACE) for treatment of squamous non-small cell lung cancer in the elderly.

Methods

From December 2017 to June 2019, 16 elderly patients with squamous non-small cell lung cancer who were treated by BACE admitted to Linyi Tumor Hospital of Shandong Province were collected. All patients were treated with 40~60 mg epirubicin with callispheres loaded with BACE. After operation, the curative effect of solid tumor was evaluated by improved solid tumor evaluation standard, the function score was evaluated by quality of life core questionnaire (QLQ-C30 version 3.0), and the advanced survival and total survival were counted. Rank sum test was used to measure the non normal distribution between groups.

Results

All the 16 elderly patients were successfully treated by DEB-BACE. One month after operation, the objective remission rate was 75.00%, and the disease control rate was 100%; three months after operation, the objective remission rate was 75.00%, and the disease control rate was 87.5%. The 6-month survival rate was 100%, the 12-month survival rate was 69.8%, the median progression-free survival rate was 7 months, and the total survival rate was 14 months. One month after interventional therapy, the scores of physical function, emotional function, general health status, fatigue, nausea and vomiting, dyspnea and insomnia were significantly better than those before treatment (Z=3.220, 2.484, 3.091, 4.642, 2.250, 6.988, 2.484; P < 0.05 or 0.01). The main adverse reactions were chest pain, fever and irritating cough, which were improved after symptomatic treatment. There were no serious complications such as spinal cord injury and cerebral embolism.

Conclusion

CalliSpheres drug-loaded microsphere through BACE is effective and safe in the treatment of squamous non-small cell lung cancer in the elderly.

Key words: Aged, Non-small cell lung cancer, Squamous cell carcinoma, Drug-eluting beads, Bronchial artery chemoembolization

Song Liu, Qiang Li, Guangji Yu, Qingdong Wang. The efficacy of Callispheres drug-eluting beads in the treatment of squamous non-small cell lung cancer in the elderly[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(03): 12-16.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2020.03.003

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2020/V07/I03/12

Figures/Tables 4

References 22

[1]	Cho BC, Kim HS, Mitsudomi T, et al. Personalized therapy on the horizon for squamous cell carcinoma of the lung[J]. Lung Cancer, 2013, 80(3):249-255.
[2]	刘松，王庆东，李强，等.支气管动脉化疗栓塞术治疗难治性、复发性非小细胞肺癌效果分析[J].中华介入放射学电子杂志，2017，5（3）：179-182.
[3]	寸江平，姜永能，宗璇，等.CalliSpheres微球联合空白微球TACE治疗中晚期肝癌的近期疗效及安全性研究[J].介入放射学杂志，2019，28（3）：237-241.
[4]	Lencioni R. New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(6):1312-1314.
[5]	Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials[J]. Eur J Cancer, 1994, 30(5):635-642.
[6]	Hamashige S, Arquilla ER. Common terminology criteria for adverse events v3.0 (CTCAE)[J]. Princip Prac Clin Trial Med, 2008, 42(4):461-533.
[7]	Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Annals Oncology, 2014, 25(suppl3):iii27-39.
[8]	王倩之，曹军，蒲兴祥，等.持续静脉泵注恩度联合DP方案治疗晚期鳞状非小细胞肺癌的有效性及安全性研究[J].成都医学院学报，2019，14（4）：440-442.
[9]	Gong W, Sun P, Mu Z, et al. Efficacy and safety of nab-paclitaxel as second-line chemotherapy for locally advanced and metastatic non-small cell lung cancer[J]. Anticancer Res, 2017, 37(8):4687-4691.
[10]	Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase ii study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer[J]. J Clin Oncology, 2018, 36(23):2386-2394.
[11]	Tournoy, Kurt G, Thomeer, et al. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals[J]. Lung Cancer, 2018, 115:49-55.
[12]	陈福涛，钟富宽，曹莉锋，等.无痛麻醉下电圈套器联合氩气刀治疗老年中央型晚期肺癌疗效观察[J].中华老年病研究电子杂志，2019，6（3）：42-46.
[13]	宋晶晶，纪建松，赵中伟，等.支气管动脉化疗栓塞联合125I粒子植入治疗老年性非小细胞肺癌疗效分析[J].介入放射学杂志，2014，23（2）：159-163.
[14]	赵倩，颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志，2017，26（11）：1052-1056.
[15]	刘娟芳，段旭华，任建庄，等.CalliSpheres载药微球与碘油经导管动脉化疗栓塞治疗原发性巨块型肝癌的疗效对比[J].中华肝脏病杂志，2019，27（6）：460-462.
[16]	李亚华，段旭华，韩新巍，等.TACE术中应用三氧化二砷CalliSpheres载药栓塞微球治疗BCLC B期原发性肝癌13例[J].介入放射学杂志，2019，28（3）：232-236.
[17]	Kennoki N, Hori S, Yuki T, et al. Trans-arterial chemoembolization therapy for refractory advanced non-small cell lung cancer with spherical embolic material--a single case report[J]. Gan To Kagaku Ryoho, 2015, 42(12):1827-1829.
[18]	Bie Z, Li Y, Li B, et al. The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer[J]. Thoracic Cancer, 2019, 10(9):1770-1778.
[19]	李晓燕，许华艳，高芳，等.克唑替尼治疗晚期或复发性ALK阳性非小细胞肺癌的疗效和安全性[J].中国肺癌杂志，2019，22（8）：488-493.
[20]	龙文兴，周定中，邹暾，等.125I粒子植入治疗非小细胞肺癌放化疗后复发的疗效观察[J].医学影像学杂志，2019，29（2）：238-240.
[21]	刘岩，罗贻雪，王梅芳，等.复方苦参注射液联合常规化疗对复发性非小细胞肺癌的疗效分析[J].肿瘤药学，2017，7（4）：460-463.
[22]	Fu YF, Li Y, Wei N, et al. Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival[J]. Radiol Medica, 2016, 121(7):605-610.

项目	治疗前	治疗后1个月	Z值	P值
躯体功能	80.6（52.2～85.5）	85.6（85.6～92.3）	3.220	<0.05
角色功能	66.7（66.7～99.5）	90.7（66.7～100.0）	0.768	>0.05
认知功能	83.3（66.7～100.0）	90.7（66.7～100.0）	1.981	>0.05
情绪功能	83.3（66.7～100.0）	95.7（83.3～100.0）	2.484	<0.05
社会功能	66.7（66.7～100.0）	100（83.3～100.0）	0.259	>0.05
总体健康状况	56.7（50.0～65.7）	65.7（65.7～82.3）	3.091	<0.05
疲乏	43.4（33.3～55.6）	12.1（11.1～33.3）	4.642	<0.01
疼痛	16.5（0～16.5）	0（0～16.5）	2.058	>0.05
恶心呕吐	0（0～16.7）	0（0）	2.250	<0.05
呼吸困难	33.3（33.3～66.7）	0（0～33.3）	6.988	<0.01
失眠	33.3（0～66.7）	0（0～33.3）	2.484	<0.05
食欲减退	33.3（0～66.7）	33.3（0～33.3）	0.646	>0.05
便秘	0（0～16.7）	0（0）	0.278	>0.05
腹泻	0（0～16.7）	0（0）	0.138	>0.05
经济影响	0（0～33.3）	0（0～16.7）	0.772	>0.05

项目	治疗前	治疗后1个月	Z值	P值
躯体功能	80.6（52.2～85.5）	85.6（85.6～92.3）	3.220	<0.05
角色功能	66.7（66.7～99.5）	90.7（66.7～100.0）	0.768	>0.05
认知功能	83.3（66.7～100.0）	90.7（66.7～100.0）	1.981	>0.05
情绪功能	83.3（66.7～100.0）	95.7（83.3～100.0）	2.484	<0.05
社会功能	66.7（66.7～100.0）	100（83.3～100.0）	0.259	>0.05
总体健康状况	56.7（50.0～65.7）	65.7（65.7～82.3）	3.091	<0.05
疲乏	43.4（33.3～55.6）	12.1（11.1～33.3）	4.642	<0.01
疼痛	16.5（0～16.5）	0（0～16.5）	2.058	>0.05
恶心呕吐	0（0～16.7）	0（0）	2.250	<0.05
呼吸困难	33.3（33.3～66.7）	0（0～33.3）	6.988	<0.01
失眠	33.3（0～66.7）	0（0～33.3）	2.484	<0.05
食欲减退	33.3（0～66.7）	33.3（0～33.3）	0.646	>0.05
便秘	0（0～16.7）	0（0）	0.278	>0.05
腹泻	0（0～16.7）	0（0）	0.138	>0.05
经济影响	0（0～33.3）	0（0～16.7）	0.772	>0.05

Please choose a citation manager

Content to export